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Abstract
The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt
diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40
recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology,
etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute
phase, through specific 23 recommendations.
Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential
development of coronary artery abnormalities in KD. Guidelines, however, should not be considered a norm that limits
treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be
required as a result of peculiar medical circumstances, patient’s condition, and disease severity or complications.
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Background
In 2008 the first Italian Kawasaki disease (KD) Guide-
lines were published. During the subsequent years new
data have been collected and updated treatment reports
have been published.
Scope
Scope of these revised guidelines is to update evidence
on the following topics:
 potential etiopathogenesis of KD;
 definition of clinical signs and symptoms, laboratory,
and instrumental tests useful for KD diagnosis;
 efficacy of therapy for KD in the acute phase of the
illness.
Users
These guidelines are directed to pediatricians who work
in hospital, family pediatricians, and general practi-
tioners who work with children affected by KD and for
families of KD patients.
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Note for users
The clinical management of each patient with KD re-
quires the application of these recommendations based
on the peculiar patient’s condition. We are pleased to
publish updated diagnostic and therapeutic indications
for both medical and paramedical staff as well as the
most accurate information for families.
Sponsorships
No person who participated in the drafting of these
guidelines has been sponsored.
Dissemination
The text has been initially discussed during the Consensus
Conference “Kawasaki Disease: Italian Guidelines” in
Rome during September 2015. The same text has been
rediscussed in the 71st National Congress of the Italian
Society of Pediatrics in Rome during June 2015, and finally
approved in the 73th National Congress of the Italian
Society of Pediatrics in Naples during June 2017.
Updates
Future updates are planned within the next 5 years, or
sooner, if the medical literature will reveal evidence
showing that these guidelines have become obsolete.
Methods
Different experts in general pediatric medicine, cardiology,
infectious diseases, rheumatology, immuno-allergology,
dermatology, radiology, or biologists experts in cell oxida-
tive stress have participated in writing these guidelines.
They have been supported by representatives of family as-
sociations. The team has been requested to systematically
analyze the most recent literature about KD to define the
following evidences dealing with etiopathogenesis, defin-
ition of clinical signs and symptoms, laboratory, and
instrumental tests for diagnosis, efficacy of therapy with
intravenous immunoglobulin and aspirin, efficacy of other
therapies in the acute phase of KD.
The basic document was the Italian KD Guidelines,
published in 2008 (Marchesi A, et al. Malattia di
Kawasaki: Linee Guida italiane. Prospettive in Pediatria.
2008;38:266–83). Additionally, further references from the
last 8 years were searched, using PubMed and Cochrane
databases.
The following key-words were used: “child”, “Kawasaki
disease” or “Kawasaki syndrome”, “coronary arteries
aneurysm” and “ectasia”, “echocardiography”, “multi-
slide computed tomography”, “angiography”, “intraven-
ous immunoglobulin”, “aspirin”, “corticosteroids”,
limiting the search to documents on humans, written in
English or Italian. Heterogeneity of the available re-
searches and their low number did not allow to perform
a meta-analysis of each item. The recommendations of
these guidelines are based on the best evidences avail-
able. Stronger recommendations are based on high sci-
entific quality data or, alternatively, on the consensus of
experts. Clinical guidelines typically provide evidence
levels based on the study design (Table 1) and reported
effectiveness (Table 2).
Introduction
Nine years have passed since the first announcement of
the Italian Guidelines for diagnosis and management of
Kawasaki disease (KD) in a national journal, but recently
many novel data and publications have become available
in relationship with this acute systemic vasculitis of child-
hood [1]. According to the 2012 “Revised International
Chapel Hill Consensus Conference Nomenclature of
Vasculitides” [2], KD involves small and medium-sized
vessels in each organ and tissue. The first KD cases were
observed in Japan in 1962, and described by dr. Tomisaku
Kawasaki in the article “Acute febrile mucocutaneous
syndrome with lymphoid involvement with specific
desquamation of the finger and the toes in children” in the
1967 journal Arerugi [3]. In general terms, we can
consider KD as a self-limited heterogeneous disease with
unknown etiology, which mostly affects infants and
children under 5 years of age.
The most significant complications in KD are coronary
artery aneurysms (CAA), but their overall incidence has
been consistently reduced by treatment with intravenous
immunoglobulin (IVIG) within 10 days of fever onset [4,
5]. Diagnosis of KD is merely clinic, based on the diag-
nostic clinical criteria, but may be supported by the re-
sults of various blood and instrumental exams. Actually,
no clinical findings or tests can be considered specific
for KD, and this circumstance makes diagnosis especially
challenging. Diagnostic difficulties depend on several
causes, such as the different times at which clinical find-
ings might appear, difficult discrimination with other
infectious and non-infectious illnesses, protean clinical
expression of the disease, occurrence of non-typical clin-
ical findings, incomplete forms of the disease, absence of
specific laboratory data, and even association with low
acute phase reactants. Concurrently, a prompt recogni-
tion of KD is essential as its prognosis depends on the
rapidity of treatment decision.
Goal of these guidelines is to recommend the best
practice in both diagnosis and management of children
Table 1 Level (class) based on study design, defined as follows
class I meta-analyses or systematic reviews from randomized controlled
trials
class II single randomized controlled trials
class III nonrandomized controlled trials
class IV retrospective case-control studies
class V number of cases without control group
class VI opinions of committees of experts and authorities
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with KD, based on the most actual scientific evidence,
and improve the overall prognosis of this disease. These
guidelines have been created for pediatricians working in
hospital, family pediatricians, and general practitioners
or nurses managing children affected by KD and for
families of KD patients.
Definition of Kawasaki disease
Typical KD
Typical or classic KD is characterized by the presence of
≥5 days of fever and ≥ 4 of the following main clinical
features: bilateral non-exudative conjunctivitis, erythema
of lips and oral mucosa, changes in the extremities, skin
rash, and cervical lymphadenopathy. Cases with defer-
vescence within the fifth day since disease onset should
be included. Diagnosis of KD is based on the presence of
the above clinical criteria: there are neither typical diag-
nostic features, nor specific diagnostic tests. These clin-
ical criteria appear within 1–2 weeks, therefore the
suspicion of KD may be initially problematic. The most
fearful KD complications are CAA, which develop in
15-to-25% of untreated patients, but only in 5% of those
treated with IVIG within 10 days following disease onset
[6]. The medical literature has recently reported an
increasing number of patients with incomplete and atyp-
ical KD.
Incomplete KD
Incomplete KD occurs in patients presenting a typical
fever without a sufficient number of main clinical criteria,
with or without CAA. This kind of KD is frequent in chil-
dren younger than 12–24 months and should be sus-
pected in every child younger than 6 months affected by
fever for more than 7 days and a documented systemic
inflammation, without any other possible cause [6].
Atypical KD
Atypical KD occurs in patients presenting a typical fever
and signs or symptoms different from the main KD clin-
ical features (i.e. meningeal inflammation, seizures, facial
paralysis, acute abdomen, acute pancreatitis, cholestatic
jaundice, arthritis, renal injury, pneumonia, etc.), with or
without CAA [6].
Recommendation 1 Typical or classic KD is diagnosed
if fever ≥5 days associated with ≥4 diagnostic criteria,
with or without CAA, or if fever lasts at least for 4 days
with ≥4 diagnostic criteria and eventual demonstration
of CAA on echocardiography.
(III - A)
Recommendation 2 Incomplete KD can be diagnosed
when patients with fever for ≥5 days lack a sufficient
number of clinical criteria (≤3) to fulfill the previous rec-
ommendation, with or without CAA.
(III - A)
Recommendation 3 Atypical KD is diagnosed if fever,
not otherwise explained, lasting for ≥5 days is associated
with classic diagnostic criteria and non-classic manifes-
tations, with or without CAA.
(III - A)
Epidemiology of Kawasaki disease
Epidemiologic data for KD are mainly available for Asia,
Europe and North America, but there are also estimates
for Australia, South America, Middle East, along with
few data also from Africa [7–11]. The latest Italian data
were produced in 1984 [12]. Studies on the spread of the
disease have shown considerable differences between
different geographical areas (Table 3), with incidence
from 3.4 up to 218.6 cases per 100.000 children less than
5 years [7–13]. The overall incidence in Asia is, on aver-
age, at least 3–4 times higher in certain countries (Japan,
Korea, China, Taiwan) rather than other (India, Thailand);
these differences are even more significant in comparison
with Europe and USA. It is likely that these differences are
due to ethnic factors combined with environmental fac-
tors, but the different ability to recognize and report the
disease should also be taken into account [11, 14, 15]. In
fact, KD incidence in the Japanese population living in
Hawaii is similar to those living in Japan [11]. The inci-
dence of KD is different according to gender, as males are
more prone to develop the disease, with a M:F ratio of
1,4-1,9:1 emerging from many studies [7–14].
Recent epidemiologic data showed an increased inci-
dence of KD during the last decades, both into Western
and Asiatic countries [7–9, 11, 13, 16, 17]: this is prob-
ably due to an improved ability for practitioners to
recognize and diagnose KD, especially in its incomplete
form [11, 18]. For instance, in Australia the incidence
has increased from 2.82 cases for 100.000 children of
age < 5 years during the decade 1980–1989 up to 9.34 cases
during the decade 2000–2009 [9]. Due to this improve-
ment, KD has become the leading cause of acquired heart
disease in children living in developed countries [1, 11, 14].
With regards to age, KD is mostly observed in children
less than 5 years in over 80% of cases [8, 15], with a peak
incidence in the first 24 months of life [11, 14]. However,
there are also a few reports of KD in neonates, teen-
agers, and even in adults [8, 14]. Such cases show a
Table 2 Classification (grade) based on effectiveness, defined as
follows
grade A highly recommended
grade B recommended
grade C recommended, but evidence is uncertain
grade D non recommended
grade E contraindicated
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tendency to develop CAA [15, 19], probably as a conse-
quence of a late diagnosis.
Several studies demonstrate a seasonality pattern for
KD, with a peak incidence in late winter and during the
spring-summer period, though this link into different
geographical areas is weak [7, 8, 11, 20]. The study of 25
different countries related to a large number of KD pa-
tients has shown a significant increase of cases during
wintertime in extra-tropical regions of the Boreal hemi-
sphere, with no significant correlation in the Austral
hemisphere [21]. A recent theory suggests a link be-
tween tropospheric air currents and the epidemic
diffusion of KD, due to the transportation of mycotoxins
from China and other areas of the Asian continent [22].
The average incidence for atypical and incomplete KD
is between 15 and 36%, with a higher distribution at the
ends of the age distribution curve (i.e. for children < 1 year
and > 5 years) [23, 24].
KD recurrence risk and incidence of familiar forms are
well-documented in the Japanese medical literature and
also in North-American studies [25–31]. In Japan the
risk of illness for a sibling of a patient with KD is in-
creased by 10 times in comparison with the general
population [25], and the probability for children with
Table 3 Incidence rates of Kawasaki disease in Asia, Europe, and North-America
Region Period Incidencea Source of data Reference
Asia
Japan 2011–2012 243.1–264.8 National survey Makino et al. 2015 [13]
Japan 2007–2008 215.3–218.6 National survey Nakamura et al. 2010 [39]
Korea 2009–2011 115.4–134.4 National survey Kim et al. 2014 [8]
Corea 2006–2008 113.1 National survey Park et al. 2011 [28]
Taiwan 2003–2006 69.0 National Health System database Huang et al. 2009 [40]
China
-Bejing 2004 55.1 Beijing’s Hospitals survey Du et al. 2007 [41]
-Shanghai 2007 53.3 Pediatric ward survey Ma et al. 2010 [42]
-Hong Kong 1997–2000 39.0 Retrospective and perspective analysis Ng et al. 2005 [43]
- Sichuan 2001 9.81 Hospital survey Li et al. 2008 [44]
India 2007 4.5 Retrospective analysis in Chandigarh, Northern India Singh et al. 2011 [45]
Thailand 2002 3.4 KD National Register Durongpisitkul et al. 2006 [46]
North America
Hawaii 1996–2006 50.4 Hawaii State Inpatient Database Holman et al. 2010 [47]
Canada 2004–2006 26.2 Clinical records’ Review in Ontario Lin et al. 2010 [48]
South America
Chile 2001–2007 6.8 National survey Borzutzky et al. 2012 [49]
Australia
Western Australia 1980–1989 2.82 ICD-9 review in Referral Hospital Saundankar et al. 2014 [9]
1990–1999 7.96
2000–2009 9.34
Middle- East
Israel 1996–2009 6.4 National Health System database Bar-Meir, 2011 [10]
Europe
United Kingdom 1998–2003 8.4 Hospitals’ data Harnden et al. 2009 [50]
Ireland 1996–2000 15.2 Ireland’s Hospital In-Patient Enquiry database Lynch et al. 2003 [51]
Finland 1992 7.2 Recovery register Salo et al. 1993 [52]
Denmark 1999–2004 4.9 Danish National Hospital Register Fischer et al. 2007 [53]
Sweden 1990–1992 6.2 Clinical records Schiller et al. 1995 [54]
France 2005–2006 9.0 Perspective survey in pediatric ward of Northen France Heuclin et al. 2009 [55]
Italy 1981–1982 14.7 Clinical records’ Review and families’interview in Northen Italy Tamburlini et al. 1984 [12]
aIncidence rates are reported per 100,000 children < 5 years of age, with exclusion of India, for which they are reported per 100,000 children < 15 years of age
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KD to have a sibling with KD is between 0.17 and 1.6%
[26–28]. This percentage is increased up to 13% for twins
[29]; 50% of familiar cases occur, on average, up to 10 days
later than the index case. Furthermore, 0.7% of Japanese
cases with KD has at least one parent with a past history
of KD [27, 32]. In Japan and Korea the overall recurrence
risk is 3% [8, 27, 30], and the main risk factors are
age < 3 years and existence of cardiac sequelae [30].
In regards with KD complications, the incidence of
CAA is approximately 15–25% in untreated patients and
less than 5% in patients treated with IVIG within 10 days
after the onset of fever [11, 19, 33]. The risk of develop-
ing CAA is greater in children aged < 12 months and >
5 years, in males, and in the recurring forms of KD, as
well as in the cases treated too late with IVIG [19, 20,
34]. In particular, infants younger than 6 months can
develop CAA up to 65% of cases, even if correctly
treated with IVIG [35]. The incidence of IVIG-resistant
KD is 15–18% in relationship with the total number of
cases and seems to have its main predictor in the pres-
ence of very high values of C-reactive protein (CRP)
during KD acute phase [34, 36, 37].
Death related to KD is mostly due to cardiac sequelae,
both in the short-term, with a peak of mortality between
15 and 45 days after the onset of fever, and in the
long-term, even in adulthood: the mortality rate in pa-
tients with KD in Japan was more than 1% up to 1974,
and has decreased to 0.1 to 0.2% from 1974 to 1993,
with a further reduction between 1993 and 2002 to
0.02–0.09% and down to 0.01% in the most recent cases
[6, 13, 38, 39]. A Japanese survey in patients who devel-
oped KD between 1982 and 1992, followed up until
2009, has documented that those patients without CAA
have a standardized mortality rate equivalent to the gen-
eral population. On the other hand, those patients with
cardiovascular involvement have a significantly higher
standardized mortality rate [38].
Etiopathogenesis of Kawasaki disease
The definite etiology of KD is unknown: the identifica-
tion of etiopathogenic mechanisms behind KD would be
essential to develop preventive strategies and focused
therapeutic strategies. Analyzing autoptic samples,
plasma cells producing IgA have been identified in the
wall of arteries of subjects with KD. Moreover, using
synthetic IgA, intra-cytoplasmic inclusion bodies with
virus-like particles have been found in intact tissue sec-
tions from children with KD, specifically in the ciliated
epithelium of medium-sized bronchi [56, 57].
From the pathophysiological point of view
Arteritis develops around the eighth-ninth day after KD
onset, and CAA start with edema formation in the
intima and media of arteries and partial rupture of the
internal and external elastic lamina. The arterial wall
does not support the internal pressure, especially dia-
stolic, and undergoes distension and deformation, lead-
ing to the formation of aneurysms. When aneurysms
begin to calcify a further pathological distension may
develop within 2–3 years [58, 59].
From the pathological point of view
There are three phases in KD:
– Acute phase. It has a mean duration of 2 weeks and is
characterized by a necrotizing vasculitis with a
predominance of neutrophils and macrophages [60, 61].
– Subacute/chronic phase. It starts after 15 days and is
characterized by the presence of lymphocytes,
plasma cells and eosinophils, which migrate to the
lumen and alter the adventitia.
– Convalescence phase. It is characterized by the
proliferation of myofibroblasts that form a concentric
mass, which progressively obliterates the lumen.
Acute phase and innate immunity The acute phase
corresponds to the activation of innate immunity: changes
begin from endothelium and progress to the adventitia;
necrosis can gradually destroy the adventitia, resulting in
ectasia or aneurysm formation, while platelets display a
pro-coagulant phenotype in the second week. Further
studies have shown that the interaction with activated
platelets is necessary for the decision by neutrophils to mi-
grate into the vessel wall or run into cell death with the
formation of “extracellular traps” [62–68].
Subacute/chronic phase and acquired immunity The
main actors of this phase are macrophages and lympho-
cytes. The infiltration of these cells starts from the internal
elastic membrane or from the media. The resolution of in-
flammation may be followed by a later stage dominated by
macrophages with a different phenotype (myeloid-derived
suppressor cells or monocyte-derived dendritic cells),
which trigger a particular aspect of acquired immunity,
producing different cytokines, and progress to a final
phase characterized by proliferation of myofibroblasts and
production of strongly pro-fibrotic cytokines (interleu-
kin-4 and interleukin-13). The involvement of innate and
acquired immunity in KD is also confirmed by the pre-
sumed association with different genetic polymorphisms
in different genes (ITPKC; BLK; FcGR2A) with regulatory
functions [69–78].
Presentation and clinical course of Kawasaki disease
General signs and symptoms
Signs and symptoms useful to the diagnosis of KD
are defined “diagnostic clinical criteria” and are repre-
sented by:
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– presence of ≥5 days of fever (including cases of
therapy-induced defervescence before day 5),
– bilateral non-exudative conjunctivitis,
– erythema of the lips and oral mucosa,
– changes in the extremities,
– skin rash,
– cervical lymphadenopathy [6].
Fever is typically high-spiking and remittent. In the
absence of appropriate therapy, fever might persist for a
mean of 11 days, but it may continue for 3 to 4 weeks
and, rarely, even longer. Bilateral conjunctival injec-
tion usually involves the bulbar conjunctivae, sparing
the limbus, the avascular zone around the iris; it is usu-
ally painless, and appears immediately following the on-
set of fever. Mild acute iridocyclitis or anterior uveitis
may be noted by slit-lamp; it resolves rapidly and rarely
is associated with photophobia or eye pain; it is mild, bi-
lateral, and resolves within 2–8 weeks. Changes of the
lips and oral cavity include erythema, dryness, fissuring,
peeling, cracking, bleeding of lips, “strawberry tongue”
with diffuse erythema of the oropharyngeal mucosa.
Rash is usually polymorphic and nonspecific: it may
show various forms, and the most common is a diffuse
maculopapular eruption, appearing in over 90% of cases,
typically within 3–5 days of fever onset. Bullae or vesi-
cles are not seen. Occasionally seen are urticarial exan-
thema, scarlatiniform rashes, erythroderma, erythema
multiform-like rash, micropustular and pustular erup-
tions [79]. Erythema of the palms and soles may some-
times accompanied by painful induration of both hands
or feet. Desquamation of fingers and toes usually begins
in the periungueal region within 2 to 3 weeks after the
onset of fever and may extend to the palms and soles.
Desquamation, usually with a “glove finger” pattern, is
not KD-specific, because it might appear in some infec-
tious diseases. Deep transverse grooves across the nails
(Beau’s lines) may appear approximately 1 to 2 months
after the disease onset. In the acute phase, erythema of
the perineal region can be observed, where early des-
quamation may occur: this is a typical sign of KD, re-
cently proposed among the clinical criteria. Cervical
lymphadenopathy is the least common of KD principal
clinical features, usually unilateral, in the anterior
cervical triangle, and involving ≥1 lymph node that is
> 1,5 cm in diameter, firm, non-fluctuant, not associated
with marked erythema of the overlying skin, and nonre-
sponsive to antibiotic therapy.
Other clinical findings of Kawasaki disease
As KD is an acute systemic vasculitis, which can affect
medium-small arteries, more clinical findings can be
present (the most frequent are in italic).
 Heart: coronaritis, pericarditis, myocarditis,
endocarditis, arrhythmia, mitral regurgitation/aortic
and tricuspidal regurgitation (in the acute phase),
aortic dilation (in a later phase), cardiac failure, shock.
 Vascular system: Raynaud’s phenomenon,
peripheral gangrene.
 Joints: arthritis or arthralgia.
 Nervous System: irritability (a particularly
suggestive symptom of KD, but not yet considered
as pathognomonic), aseptic meningitis,
encephalopathy, seizures, ataxia, sensorineural
hearing loss, transient unilateral peripheral facial
nerve palsy.
 Gastrointestinal tube: diarrhea, vomiting,
abdominal pain, acute abdomen, hepatic
enlargement and jaundice, acute acalculous
distention of the gallbladder (hydrops), acute
pancreatitis, cholestatic jaundice, retropharyngeal
abscesses are described in 3.6% of cases [80, 81].
 Urinary system: aseptic pyuria, proteinuria,
urethritis, testicular swelling.
 Skin: erythema and induration at the site of a
previous bacillus Calmette-Guérin vaccination [82].
 Respiratory system: cough, rhinorrea, slow-
resolution pneumonia, pulmonary nodules, and lung
infiltrates.
Clinical course of Kawasaki disease
KD clinical course can be divided into three clinical phases:
acute, subacute, and convalescence phase (Table 4).
Differential diagnosis of Kawasaki disease
Table 5 shows the most frequent illnesses to consider in
the differential diagnosis with KD, subdivided into infec-
tious and non-infectious. Excluding all possible infec-
tious diseases is recommended. A simultaneous viral or
bacterial infection cannot be excluded, and consequently
the identification of viral or bacterial agents cannot ex-
clude KD diagnosis and also IVIG treatment. A concomi-
tant bacterial infection must additionally be treated with
antibiotics. It is also important to emphasize that a
Table 4 Clinical phases of Kawasaki disease
Acute phase (first and second week):
- presence of fever and other acute classic signs
Subacute phase (third and fourth week):
- it begins with defervescence and when other acute signs vanish
- irritability, anorexia, and conjunctivitis can still be present
- digital skin desquamation
- thrombocytosis
- coronary artery aneurysms might appear
- in this phase there is a risk of sudden death
Convalescence phase (fifth to eighth week):
- all disease signs and symptoms disappear
- inflammatory indexes return completely to normal
- endothelial dysfunction might cause cardiovascular acute events
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positive response to IVIG does not automatically confirm
diagnosis of KD, as other diseases (e.g. sepsis) can be also
treated with this same therapy. Finally, coronary artery
dilation is not pathognomonic of KD, and indeed it can be
present in the acute febrile phase of both infectious
(Epstein-Barr virus infection, and Rocky mountain spotted
fever) and inflammatory diseases (systemic onset-juvenile
idiopathic arthritis, Takayasu disease, polyarteritis nodosa,
and systemic lupus erythematosus) [83–88].
Cardiovascular complications of Kawasaki disease
The most relevant complications in KD are represented
by CAA, and different remodeling phenomena will affect
their prognosis. The coronary artery dilation may start as
ectasia, slight expansion (up to less than 5 mm in diameter),
moderate dilation (from 5 to less than 8 mm) up to giant
aneurysms (more than 8 mm in diameter). The majority of
coronary artery aneurysms occur in the proximal segments
and at the branch level. KD patients with normal coronary
arteries or with mild ectasia at 6 weeks since disease onset
have an overall good prognosis [6, 89, 90]. On the contrary,
patients with persistent aneurysms are at risk of stenosis
and/or thrombosis of the same arteries. Giant coronary an-
eurysms do not revert to a normal morphology (see Tables 7
and 8 for details). The repair of affected vessels occur by
wall remodeling without total “restitutio ad integrum”, but
with progressive intimal hyperplasia and fibrosis, that lead
to stenotic changes of the coronary artery, with risk of
thrombosis, myocardial heart attack, and sometimes even
sudden death. Rarely new aneurysms appear later in pa-
tients with pre-existing aneurysms and, if this occurs, they
represent post-stenotic dilations. In rare cases aneurysms
can develop in the axillary or celiac arteries. Other different
cardiovascular complications may develop less frequently in
patients with acute KD, and include myocarditis, pericardi-
tis or pericardial effusion with myopericarditis, valvular
insufficiency, and, rarely, arrhythmias. A specific treatment
may be required for these manifestations as well as for
cardiac dysfunction or heart failure [91, 92] (see part II).
Other complications of Kawasaki disease
Anemia, hypoalbuminemia, electrolyte imbalance, liver
dysfunction, cholecystitis, seizures, diarrhea, vomiting,
dehydration, and heart failure might occur and specific
treatments may be required. The occurrence of macro-
phage activation syndrome has also been reported
[93–95], while another potential complication is KD
shock syndrome [96] (see part II).
Recurrence of Kawasaki disease
Recurrence of KD ranges from 1.4 to 3% (respectively
from the Chinese and Japanese epidemiologic studies
available). Often KD symptoms are the same as for the
first episode. A longlasting fever, IVIG resistance, elevated
AST levels, reduced hemoglobin are all risk factors related
to KD recurrence [97]. A recurring KD is associated with
a higher risk of development of CAA. Autoinflammatory
syndromes should be considered for a comprehensive dif-
ferential diagnosis in childhood [98].
Investigations in Kawasaki disease
Diagnosis of KD is based on the sole clinical diagnostic
criteria [5, 6], because neither pathognomonic clinical fea-
tures nor specific diagnostic tests exist. A prompt diagno-
sis is crucial because prognosis relies on the rapidity of
treatment. Consequently, in case of suspected KD, it is
important to recommend patient’s hospitalization to per-
form a thorough evaluation and confirm diagnosis. Unfor-
tunately, laboratory tests are nonspecific, though they can
support KD diagnosis (see Table 6) [1, 6] in patients with
suggestive clinical features of KD.
Laboratory findings
Leukocytosis is typical during the acute phase of this dis-
ease with predominance of immature and mature granulo-
cytes. Anemia occurs commonly and is normochromic
normocytic: it resolves with the resolution of inflamma-
tion. Elevation of acute-phase reactants as ESR and CRP is
frequent, but sometimes they are only slightly increased.
Moreover, ESR is elevated by IVIG therapy, and therefore,
a decreased ESR during follow-up should not be used to
assess response to treatment with IVIG. Thrombocytosis
is characteristic in the second week of the disease, peaking
in the third week and normalizing by 4 to 6 weeks after
onset in most cases; thrombocytopenia is rare, but may
occur in the first 1 to 2 weeks of illness: thrombocytopenia
Table 5 List of illnesses entering in differential diagnosis with Kawasaki disease
Infectious illnesses Non-infectious illnesses
. viral (rubella, adenovirus, enterovirus, cytomegalovirus, Epstein-Barr virus, parvovirus B19, human herpesvirus 6)
. scarlet fever
. Mycoplasma pneumoniae infection
. toxic shock syndrome
. staphylococcal scalded skin syndrome
. bartonellosis
. Rocky mountain spotted fever
. tularemia
. leptospirosis
. drug hypersensitivity reaction
. Stevens-Johnson syndrome
. juvenile idiopathic arthritis
. polyarteritis nodosa
. autoinflammatory syndromes
. sarcoidosis
. acrodynia
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can be a sign of disseminated intravascular coagulation
and is a risk factor for the development of coronary artery
abnormalities. In patients with arthritis, arthrocentesis
typically yields purulent-appearing fluid with a white
blood cell count of 125,000 to 300,000 per mm3, a normal
glucose level and negative culture tests. Mild to moderate
elevations in serum transaminases or gamma-glutamyl
transpeptidase occur in 40 to 60% of patients, and mild
hyperbilirubinemia occurs in 10%. Hypoalbuminemia is
common and associated with more severe and more pro-
longed acute disease. Urinalysis may show pyuria in up to
80% of children. In children who undergo lumbar punc-
ture, 30% demonstrate pleiocytosis with a mononuclear
cell predominance, normal glucose levels and generally
normal protein levels.
Recommendation 5 Laboratory data are nonspecific in
KD and can only support diagnosis in patients with sug-
gestive clinical features.
(V - B)
Dyslipidemia and risk of atherogenesis in patients with
Kawasaki disease
A disrupted lipid metabolism may characterize the acute
phase of KD, and finally give a reduction of serum total
cholesterol, particularly HDL, and increase of triglyceri-
demia. Some studies have reported that this altered lipid
state might persist over a period of 3 years after KD
diagnosis. The effect of dyslipidemia on the cardiovascu-
lar risk is not completely clear: while some studies
proved early ultrasound signs of reduced elasticity and
abnormal carotid intima-media thickness in young
adults with history of KD, subsequent studies were not
confirmatory [99–102]. The presence of CAA seems also
to correlate more significantly with lipid metabolism
disorders, whereas this finding remains controversial in
patients without CAA [103].
Pro-inflammatory conditions and pro-coagulant activity of
the peripheral blood in patients with Kawasaki disease
The formation of reactive oxygen and nitrogen species
in KD is known to generate a systemic pro-oxidant sta-
tus in the blood, which might lead to altered red blood
cell and platelet homeostasis with propensity to develop
a cascade of procoagulant complications and focal endo-
thelial damage [104–106]. Particularly, inflammation as-
sociated with systemic pro-oxidant state can play a key
role in the pathogenesis and progression of KD. Reactive
oxygen and nitrogen species (collectively called RONS)
generate a pro-oxidant status in the blood that promote
an oxidative and nitrative stress as well as a redox imbal-
ance, leading to altered cell signaling and functions.
Whole blood from patients with KD show increased
levels of RONS, while scavenger activity of RONS might
be significantly decreased during the acute phase of KD.
Finally, thrombocytosis might result from a defect of cell
death, as suggested by studies about annexin V positive
and negative platelets, and the propensity to develop
coronary damage may be associated with altered platelet
homeostasis [104–106].
Echocardiography
Echocardiography should be performed by a cardiologist
with experience in the pediatric age, and the coronary
artery districts to visualize include left coronary artery,
descending coronary artery, circumflex artery, left anterior
artery, right coronary artery, and posterior descending
coronary artery. The presence of marked perivascular
brightness, the absence of the physiological gradual reduc-
tion of coronary artery caliber, and a mild ectasia, if
isolated, are not indicative of KD; however, these findings
could be considered a positive echocardiographic sign
when they are all three simultaneously present (expert
opinion) to suggest KD diagnosis. Changes in the left
ventricular function, presence of mild mitral or aortic
regurgitation, and pericardial effusion may be present in
the KD acute phase, though they should not be considered
sufficient for confirming KD diagnosis [111]. Stenosis and
thrombosis might appear in later phases and/or in older
Table 6 Main laboratory abnormalities in patients with Kawasaki
disease
BLOOD CELL COUNT
white blood cells ↑, maximal elevation of polymorphonuclear cells
↓ rarely
red blood cells ↓, normal mean corpuscular volume
platelets ↑, typically in the II and III week, normalization
in 4–8 weeks
if ↓ suspect disseminated intravascular
dissemination
INFLAMMATORY PARAMETERS
erythro-sedimentation
rate (ESR)
↑, slow normalization
C-reactive protein (CRP) ↑, fast normalization
LIVER FUNCTION TESTS
transaminases ↑
bilirubinemia ↑
gamma-glutamyl
transpeptidase
↑
albuminemia more severe and prolonged illness if ↓
OTHER LABORATORY TESTS
urine white blood cells > 10/high field powered
cerebrospinal fluid aseptic meningitis (presence of mononuclear
cells, normal glucose/proteins)
synovial fluid purulent-appearing fluid, white blood cells
125.000–300.000/mm3, normal glucose level
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patients, when the coronary arteries are more difficult to
see on routine ultrasound investigations. Stress echo with
the administration of drugs (dobutamine) is now widely
used for the diagnosis and follow-up of secondary ische-
mic heart disease in patients with KD [112, 113].
Recommendation 6 Bidimensional and color-Doppler
echocardiography and/or associated techniques (tissue-
Doppler imaging, 3D echocardiography imaging) are piv-
otal modalities to perform cardiac assessment of patients
with KD, as they are non-invasive repeatable investigations,
characterized by both high sensitivity and high specificity.
(V - A)
Criteria for the recognition of KD-related CAA have
been defined by the Japanese Ministry of Health, based on
the absolute values of coronary arteries size among pa-
tients of different age groups [107]. However, in cases that
did not meet these criteria it was reported an increased
incidence of CAA at different phases of the disease, com-
pared to patients belonging to homogeneous and compar-
able groups for age and body surface area [108].
The concept of z-score was introduced several years
ago to compare the coronary artery diameter to the body
surface area and measure the standard deviation from
the average in Z units (SD, z-score), using specific no-
mograms (www.parameterZ.com). This is recommended
for the right coronary, left anterior descending, left main
coronary arteries, and also for other vascular structures
such as the aortic ring and ascending aorta. We define a
z -score < 2.5 normal, viceversa pathological if ≥2.5, with
features of “ectasia” or “aneurysm” depending on the
morphological characteristics observed. This standard
deviation system should be used in the initial diagnosis
of CAA when there is a suspicion of KD, when the selec-
tion may be more “coarse” to avoid losing patients that
may be at risk in the near future; conversely, size criteria
should be used in the follow-up of KD patients, particu-
larly if localized coronary artery injuries have been found
(see Table 7) [1, 109, 110].
The severity of Kawasaki disease is classified into the
following 5 grades on the basis of findings of echocardi-
ography and selective coronary angiography or other
methods (see Table 8) [110].
In up to 80% of patients with significant dilation or
aneurysms at later echocardiograms some abnormality is
evident on the initial echocardiogram obtained in the
first 10 days of illness [1]. The largest proportion of
patients with coronary artery abnormalities will have
dilation only, characterized by luminal measurements out-
side the normal range, but with a maximal z-score < 2.5.
Dilation resolves within 4 to 8 weeks in most cases..
Recommendation 7 Echocardiogram must be per-
formed in all patients with a diagnosis of KD; then after 2,
4, and 8 weeks since KD onset in the uncomplicated cases,
as CAA can be detected in the subsequent weeks after
diagnosis.
(VI - B)
Recommendation 8 Persistently febrile non-responders
KD patients with CAA, impaired left ventricular func-
tion, mild/moderate mitral regurgitation or significant
pericardial effusion need a more frequent echocardio-
gram check-up (at least twice per week).
(VI - A)
The presence of marked perivascular brightness, the
absence of the physiological gradual reduction of coron-
ary artery caliber and mild ectasia, if isolated, are not
indicative of KD. These findings could be considered a
positive echocardiographic KD sign when they are all
three simultaneously present (expert opinion). Changes
Table 7 Classification of coronary artery aneurysms in the acute
phase of Kawasaki disease and severity classification
Dilation: diameter≥ 2.5 SD
Small aneurysm:
localized dilation showing an inner diameter≤ 4 mm (in children
≥5 years: the internal diameter of a segment < 1.5 times compared to
an adjacent segment)
Z-Score≥ 2.5 to < 5
Medium aneurysm:
aneurysm showing an inner diameter > 4 mm and < 8 mm(in children
≥5 years: the internal diameter of a segment 1.5~ 4 times compared to
an adjacent segment)
z-score≥ 5 to < 10
Giant aneurysm:
aneurysm showing an internal diameter≥ 8 mm(in children ≥5 years:
the internal diameter of a segment > 4 times compared to an adjacent
segment)
z-score≥ 10
Table 8 Severity classification of coronary artery aneurysms in
Kawasaki disease
I. No coronary dilatation: patients with no coronary dilatation including
those in the acute phase
II. Transient coronary dilatation during the acute phase: patients with
slight and transient coronary dilatation which typically subsides within
30 days after onset
III. Regression: patients who still exhibit coronary aneurysms meeting the
criteria for dilatation or more severe change on day 30 after onset,
despite complete disappearance of changes in the bilateral coronary
artery systems during the first year after onset, and who do not meet
the criteria for Group V
IV. Remaining coronary aneurysm: patients in whom unilateral or
bilateral coronary aneurysms are detected by coronary angiography in
the second year or later and who do not meet the criteria for Group V
V. Coronary stenotic lesions: patients with coronary stenotic lesions
detectable by coronary angiography
(a) Patients without ischemic findings: patients without ischemic
signs/symptoms detectable by laboratory tests or other examinations
(b) Patients with ischemic findings: patients with ischemic signs/
symptoms detectable by laboratory tests or other examinations
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in left ventricular function, presence of mild mitral or
aortic regurgitation, pericardial effusion may be present
in the KD acute stages but should not be considered suf-
ficient for the diagnosis, as they can also be found in
other inflammatory disease.
Moreover, pericarditis, mitral insufficiency, impairment
of systolic function, indirect signs of inflammation, can be
predictive of coronary lesions, which could be non per-
manent. Actually echocardiographic sensibility and speci-
ficity is not so clear in diagnosis of stenosis and thrombi.
These lesions appear usually in later phases and in
older patients, when coronary arteries system is more
difficult to see.
Echocardiography remains the instrument of choice to
identify CAA during the acute phase of KD up to the
first 6 weeks after onset. However, computed tomog-
raphy (CT) or magnetic resonance (MR) angiography
can be required for an accurate risk stratification via
evaluation of the vascular system, especially in growing
children. Advanced cardiovascular imaging techniques
for a more specific assessment of cardiovascular sequelae
in KD are CT and MR angiography. Multi-slice CT is an
established tool for a less-invasive assessment of the car-
diovascular system in adults: the diffusion of such a
technique for coronary artery studies in children with
KD is still limited. This is mainly due to radiation expos-
ure issues, need for general anesthesia, need for
beta-blockers (to obtain regular heart rates ideally lower
than 65–70 beats per minute), and enhancement con-
trast infusion. A dual-source CT (DSCT) provides excel-
lent quality images and low radiation doses for
diagnosing KD-related CAA in infants and children
[114]. Moreover, DSCT is superior to echocardiography
in the detection of CAA located in the peripheral parts
of vessels [115]. New generation scanners enable a very
rapid body CT scan (less than 1 s), permit central/per-
ipheral aneurysm detection, and reduce the need for
general anesthesia [116]. The majority of magnetic res-
onance (MR) angiography studies on KD have been per-
formed using 1.5 Tesla magnets fully equipped for
cardiac investigation with a set up for general anesthetic
support, using a comprehensive scan protocol which in-
cludes functional imaging with breath-hold, ECG-gated,
2D steady-state free precession, contrast-enhanced study
for whole body detection of central and peripheral
aneurysmal dilations during intravenous infusion of con-
trast (gadolinium at a dose of 0.1 mmol/kg of body weight),
or myocardial perfusion imaging at rest and after pharma-
cological stress [117–119]. Advanced imaging studies with
cardiovascular CT or MR may be reasonable in selected
patients to help in the management decisions, as cardiac
catheterization in the acute phase of KD has been associ-
ated with a greater incidence of adverse vascular events [1].
Conversely, there are limited data regarding cardiac
function after the acute phase of KD. Subclinical dysfunc-
tions may be missed when assessing left ventricular systolic
function using conventional echocardiography. Recently,
speckle-tracking echocardiography is emerging as an
effective tool for determining global longitudinal and cir-
cumferential strain and myocardial deformation in patients
with KD, especially in mid-long term follow-up [120].
Recommendation 9 Cardiovascular CT scan, ideally
with a DSCT scanner, should be used in patients with
KD to:
– confirm CAA (and rule out false positive cases due
to coronary artery anomalies or anatomical variants)
– detect middle-distal CAA (not usually seen at
routine echocardiograms)
– more accurately define caliber and morphology of
CAA
– identify coronary artery thrombosis or occlusions
– evaluate other aneurysms, both central or
peripheral, in the entire body
– reveal myocardial ischemia or reassess caliber and
morphology of CAAs and better define their
treatment.
(VI - C)
Cardiovascular CT scan in the further follow-up
phases can be used to monitor the results of previously
treated coronary arteries (e.g., after stenting) (see Part II
for details).
Recommendation 10 Cardiovascular MR angiography
should be used in patients over 8 years with KD to:
- confirm CAA (and rule out false positive cases due
to coronary artery anomalies or anatomical variants).
- identify other aneurysmal dilations, either central or
peripheral, in the vascular system.
- assess biventricular global/regional systolic function.
- depict any myocardial scar with contrast-enhance-
ment and visualize gross coronary artery anatomy.
(VI - C)
In the further follow-up phases cardiovascular MR
angiography can be used to detect areas of inducible
myocardial ischemia during pharmacological stress (e.g.,
adenosine stress perfusion test) (see Part II for details).
Treatment of Kawasaki disease
In this first part of the Guidelines the only treatment of
the acute phase will be discussed.
Treatment of the acute phase of Kawasaki disease
The main goal of treatment in the acute phase of KD is
suppressing the inflammatory reaction and minimizing
the risk of developing CAA. A host of data about the
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administration of intravenous immunoglobulin (IVIG) as
initial “first-line” treatment in children with KD has
confirmed the efficacy and safety of this therapy. In fact,
following IVIG introduction since the early 1980s, the
overall incidence of CAA is gradually decreased [121].
IVIG should be started before the 7th day of illness: in
fact, histological studies have shown that KD arteritis
typically develops around the 8-9th day after disease on-
set. In about 80% of cases, defervescence occurs within
48 h after IVIG infusion.A persistent or reoccurring
fever after 48 h since a first administration of IVIG con-
figures the framework of IVIG-resistant KD (approxi-
mately 15–20% of patients). Nowadays there is no still
effective and universally accepted treatment for these
patients, and therefore treatment of these challenging
patients will have to be cut out ad hoc. In addition, there
is no universally accepted classification system for evalu-
ating the severity of KD or possibility to modulate ther-
apy: many scoring systems have been proposed, but they
have shown little sensitivity in the Western populations
than in Japanese one [122].
The initial treatment of KD acute phase includes the
combined use of IVIG and aspirin (acetylsalicylic acid,
ASA).
Intravenous immunoglobulin (IVIG)
Rational
High-dose IVIG is the most effective anti-inflammatory
treatment to reduce the risk of CAA in patients with KD
[123–126], as confirmed by a systematic Cochrane
review [127]. IVIG is derived from human plasma and
requires an informed consent before use.
Mechanism of action
Since KD causes are unknown, the mechanisms of
action of IVIG remain speculative. The hypothesized
action mechanisms mainly are anti-inflammatory and
mediated by the Fc receptor, B and T cells, and dendritic
cells [128–131].
Therapeutic indication
IVIG is indicated in the acute phase of typical, incom-
plete and atypical KD; IVIG should not be administered
if fever spontaneously disappears, if CAA are not shown,
or if inflammatory markers (ESR and CRP) are within
normal limits.
Dosage
A dose of 2 g/kg of body weight in a single infusion
significantly reduces the incidence of CAA, and is able
to suppress both inflammation and fever. The rate of
infusion of IVIG varies slightly for different products,
though IVIG is usually administered in 12 h in North
America and in 24 h in Japan. Currently there is no
apparent difference for efficacy among different brands
of IVIG.Close monitoring and reduced rate of infusion
are necessary during the first 30–60 min in order to re-
duce the risk of anaphylaxis. During the administration of
IVIG, presence of fever or a further rise in temperature do
not contraindicate the administration which should not be
withdrawn. IVIG should be started within 7 days since KD
onset to rapidly reduce inflammation, as in the 8-9th day
CAA might appear. One study compared patients treated
with IVIG within the 5th day of illness with those who
received IVIG between the 6th and 9th day: the groups
did not differ in the incidence of resistance to therapy or
number of days of hospitalization, though 1 year later
those who received IVIG earlier had a lower incidence of
coronary artery disease [132]. In addition, we must con-
sider that KD enters a differential diagnosis with many
diseases, therefore treatment of suspected cases before the
5th day of fever could intercept patients with other diag-
noses. Furthermore, the administration of IVIG is expen-
sive and might be related to even severe, although
infrequent, side effects. Treatment before the 5th day of
fever should be reserved to exceptional cases of unequivo-
cal diagnosis of KD [133].
Effectiveness
IVIG is quite safe and, at present, are the most effective
therapy in KD.
Side effects
The donated blood is carefully screened to confirm the
absence of HBsAg, anti-HCV antibodies, anti-HIV-1/2
and anti-HTLV-1 antibodies, and to verify the absence
of nucleic acid from HIV, hepatitis B virus, hepatitis C
virus, hepatitis A virus, and human parvovirus B19.
Using the existing pharmaceutical production processes,
the absence of viruses cannot be determined with 100%
certainty, but there have been no reports of viral infec-
tions caused by IVIG infusion. Therefore, side effects are
rare, and include chills, hypotension, anaphylactic reac-
tions, aseptic meningitis, hemolytic anemia, abnormal
liver function tests, jaundice, acute renal failure,
thrombocytopenia, and pulmonary edema. Patients
should be closely monitored, particularly immediately
after the start of IVIG infusion and when increasing the
infusion rate. Patients may also develop cardiac dysfunc-
tion or acute heart failure, and therefore it is necessary
to prevent a sudden increase of circulating blood
volume. When using IVIG, it is necessary to consider
allergic reactions in response to IVIG in patients with
IgA deficiency, the risk of a further deterioration of renal
function in patients with a previous kidney damage,
thromboembolic events such as cerebral infarction or
myocardial infarction in patients with previous or
present cardiovascular or cerebral damage [134, 135].
Marchesi et al. Italian Journal of Pediatrics  (2018) 44:102 Page 11 of 18
Recommendation 11 IVIG must be administered at
dose 2 g/kg of body weight in a single infusion, within
the first 7th day of illness, anyway within the 10th day.
Administration should be performed in 12 h if patient’s
cardiac function is normal, or in 16–24 h for patients
displaying cardiac failure.
(I - A)
Recommendation 12 IVIG should also be administered
to children presenting after the 10th day of illness in
case of:
– persistent fever
– no more fever but aneurysms and ongoing systemic
inflammation, as shown by elevation of CRP.
(V- B)
Aspirin (acetylsalicylic acid, ASA)
Rational
The mechanism of action of aspirin differs according to
the dosage: medium-high dosages are used for the
anti-inflammatory effect in the acute febrile phase of
KD, while lower dosages are used for the antiplatelet ef-
fect in the subacute phase, when the risk of CAA is
higher.
Mechanism of action
ASA blocks the synthesis of prostaglandin E2 from ara-
chidonic acid, thereby exerts its anti-inflammatory effect,
but also inhibits platelet aggregation by blocking the
synthesis of thromboxane A2 by cyclooxygenase.
Indications
ASA is approved for all patients with KD.
Dosage
Associated with IVIG in the initial treatment, ASA
anti-inflammatory dosage varies from 80 to 100 mg/kg/
day in the USA to 30–50 mg/kg/day in Japan, subdivided
into four doses [136]. Then, 48 h after defervescence,
aspirin can be used at an antiplatelet dosage: 3–5 mg/
kg/day. The duration of treatment is 6–8 weeks in KD
patients without CAA. However, in patients with CAA,
antiplatelet therapy is continued until resolution of the
lesions or indefinitely in case of persistence.
Effectiveness
Many studies do not demonstrate that the anti-inflam-
matory effect of aspirin reduces the development of
CAA; furthermore, recent studies suggest to start imme-
diately with an antiplatelet dosage in the acute phase of
KD, in consideration of the procoagulant state of plate-
lets in KD [137, 138].
Side effects
The use of ASA at medium-high dosage can be associ-
ated with risk of hemorrhage, asthma, liver failure,
gastrointestinal ulcers, hives, rash, kidney failure, and
loss of appetite. Liver failure is frequent, therefore as-
sessment of transaminase level is mandatory; in case of
changes it is necessary to reduce ASA dosage or stop
treatment. In case of chickenpox (varicella) and flu the
possibility of Reye’s syndrome should be considered,
while at low dosage of ASA the occurrence of this syn-
drome is rare.
Recommendation 13 In the KD acute phase ASA must
be administered at a daily dosage of 30–50 mg/kg di-
vided into 4 doses until 48 h after disappearance of
fever.
(I - A)
Recommendation 14 When high-dose ASA is discon-
tinued, low-dose ASA (3-to-5 mg/kg per day) must be
started.
(I- A)
In the medical literature there is an ongoing debate
about discontinuation of aspirin depending on the size
of CAA.
Recommendation 15 In patients without CAA
low-dose ASA is to be discontinued 8 weeks after KD
onset. In children who develop CAA low-dose ASA may
be continued until the resolution of vascular lesions or
indefinitely in case of its persistence.
(V - B)
Attempting to identify which KD patients should be
unresponsive to treatment with IVIG or predicting the
ones who might display a significant risk of developing
cardiologic sequels are two issues of outstanding prior-
ity. Many efforts have been made to discriminate as soon
as possible the cohort of IVIG nonresponder patients in
order to undertake a more aggressive treatment since
KD onset: different scores have considered multiple fac-
tors, such as patient’s age, sex, duration of disease, white
blood cell count, hematocrit, platelet count, C-reactive
protein, transaminases, total bilirubin, albumin, sodium,
however none of them has shown high sensitivity in
Caucasian populations [139].
High-risk KD patients are younger than 12 months,
show elevated CRP, elevated aminotransferase level, hypo-
albuminemia, severe anemia at disease onset and might
display early development of CAA, signs of macrophage
activation syndrome or shock.
Recommendation 16 High-risk KD patients should
receive initial therapy with IVIG + ASA + corticosteroid
(1 pulse of intravenous methylprednisolone: 30 mg/kg/
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day as a single administration or intravenous prednisone:
2 mg/kg/day, then tapered orally).
(I - B)
Vaccines: The potential interactions with IVIG and ASA
The analysis of KD cases reported by the Vaccine
Adverse Event Reporting System (VAERS) of USA up to
2007 showed that the incidence of this disease in chil-
dren who received all registered vaccines was similar or
even less than the incidence expected on the basis of the
known epidemiology of KD in Italy. On the contrary, the
administration of vaccines is associated with a lower
frequency of occurrence of KD at least for the 42 days
following vaccine administration without differences
among the various preparations [140]. A recent study,
reporting data of 1.721.186 children between 0 and
6 years old, followed by a long period of time, shows that
in KD patients the frequency of administration of vac-
cines in the 42 days preceding the onset of the syndrome
was lower than controls non-vaccinated [141].
KD treatment with IVIG does not significantly interfere
with all inactivated vaccines, oral attenuated live virus
vaccines (rotavirus, typhoid vaccination), live virus nasal
vaccines (flu), bacillus Calmette-Guérin (BCG) vaccine,
and yellow fever vaccine. Consequently, these vaccines
can be administered concurrently with the administration
of IVIG or at any time after administration of IVIG in KD.
It is usually recommended to wait 10 months before
administration of vaccine against measles, mumps, rubella
(MMR), varicella (V), and MMRV vaccines, as this could
interfere with the immune response to MMR, V and
MPRV antigens, which may result in a reduced immuno-
genicity [142].
In KD patients who are receiving ASA flu vaccination
is strongly recommended for the known relationship be-
tween the influenza virus infection and the development
of Reye’s syndrome in children and adolescents treated
with salicylates [143]; for the same reason it is discussed
about the administration of V vaccine in children with
KD on ASA prophylaxis. Pharmaceutical companies pro-
ducing vaccines containing V (as a monovalent prepar-
ation or as MPRV formulation) indicate on the package
that subjects who receive salicylates should discontinue
these medications for 6 weeks following the administra-
tion of this vaccine [144]. This attitude is not shared by
several scientific authorities for the lack of data indicat-
ing an actual risk of the vaccine in these patients. Some
experts suggest deciding whether or not to vaccinate
against chickenpox based on an accurate assessment of
the risk of vaccination and those of the disease in the
individual patient. If you decide to vaccinate KD chil-
dren on ASA with V or MPRV vaccines, ASA might be
replaced by clopidogrel: its dosage is 1 mg/kg/day in a
single dose (up to a maximum of 75 mg/day in children
> 2 years, or 0.2 mg/kg of body weight in children
< 24 months). Vaccination against V or MPRV could be
given after 48 h of stopping ASA, and ASA should be
restarted by suspending clopidogrel 6 weeks after
vaccination [145]. If a KD patient requires treatment with
biologic drugs, it should be assumed that there may be
problems of reduced immunogenicity and safety of vac-
cines [146–149]. As for the live-virus attenuated vaccines,
even if there is no evidence of adverse events in the few
studies available, it is believed that further studies are
needed to confirm their safety; therefore, it is important
that the patient receives two doses of MMR vaccine and is
adequately protected even against varicella in case of no
history of a natural disease for at least 1 month before the
start of biological drugs [150].
Recommendation 17 As the administration of every
type of vaccine does not increase the risk of reappear-
ance of KD, vaccinations are to be administered in KD
patients.
(III - A)
Recommendation 18 All inactivated vaccines, rotavirus,
oral typhoid, intranasal anti-flu, BCG vaccines and the
vaccine against yellow fever may be administered con-
currently with the administration of IVIG or at any time
after administration of IVIG in KD patients.
(V - A)
Recommendation 19 The MMR, V and MPRV vaccines
should be administered 10 months after the administra-
tion of IVIG in KD patients to avoid a reduced immune
response as result of the specific high antibody titer
against the antigens contained in IVIG.
(VI - B)
Recommendation 20 Influenza vaccination is highly
recommended in KD patients assuming ASA due to the
increased risk of Reye’s syndrome.
(III - A)
Recommendation 21 If a KD patient assuming ASA
has to be vaccinated with V or MPRV vaccines, ASA can
be replaced by clopidogrel because of a theoretical risk
of Reye’s syndrome associated with the attenuated
varicella-zoster virus contained in these vaccines. Its
dosage is 1 mg/kg/day in a daily administration, up to a
maximum 75 mg/day (adult dose), or 0.2 mg/kg of body
weight in children < 24 months. Additionally, V or
MPRV vaccination can be given after 48 h of stopping
ASA, and ASA can be restarted after suspending clopi-
dogrel 6 weeks after vaccination.
(VI - C)
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Recommendation 22 It is recommended to administer
all inactivated vaccines following the routine schedule in
patients with KD receiving biological drugs.
(V - B)
Recommendation 23 Attenuated live virus vaccines
should be administered 1 month before beginning ther-
apy with biologics in patients with KD, but they are not
recommended during treatment with biologics.
(VI - C)
Discussion
Not applicable.
Conclusion
Goal of these guidelines is to recommend the best practice
in both diagnosis and management of children with KD,
based on the most actual scientific evidence, and improve
the overall prognosis of this disease. In this first part of
guidelines we carried out hypothesis about etiology of KD,
because the identification of its etiopathogenic mecha-
nisms would be essential to develop preventive and
focused therapeutic strategies. We improved definition of
incomplete and atypical KD, avoiding the loss of potential
patients. We tried also to evaluate as dyslipidemia, proin-
flammatory conditions and procoagulant activity might
act as cardiovascular risk factors in KD. Concerning
instrumental techniques, we strongly emphasized the
suggestion of implementing the use of standard deviation
system of z-score in echocardiography, to avoid losing
patients during the acute phase of KD. We explained
other advanced cardiovascular imaging techniques, i.e.
computed tomography (CT) or magnetic resonance (MR)
angiography, which can be required for an accurate risk
stratification of the vascular system. Concerning therapies,
we revised timing if IVIG infusion as well as dosages of
aspirin. Attempting to identify which KD patients should
be unresponsive to treatment with IVIG or predicting
the ones who might display cardiologic sequels, we in-
troduced a stratification in low and high-risk patients
with different therapeutic indications. Finally we inves-
tigated the potential interactions between vaccines and
both IVIG and ASA.
Abbreviation
ASA: Acetylsalicylic acid; BCG: Bacillus Calmette-Guérin; CAA: Coronary artery
aneurysms; CRP: C-reactive protein; CT: Computed tomography;
ESR: Erythrocyte sedimentation rate; HbsAg: Hepatitis B surface antigen;
HCV: Hepatitis C virus; HIV: Human Immunodeficiency virus; HTLV-1: Human
T-cell leukemia virus type 1; IVIG: Intravenous immunoglobulin; KD: Kawasaki
disease; MMR: Measles, mumps, rubella; MMRV: Measles, mumps, rubella,
varicella; MR: Magnetic resonance; V: Varicella
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